{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22"],"submitter":["Kao Y"],"pubmed_abstract":["Glioblastoma (GBM) is the most common type of primary brain tumor. Patients with GBM have poor survival outcomes. Isolated components of <i>Momordica charantia</i> have anticancer effects. However, the bioactivity of <i>M. charantia</i> extracts against GBM remains unknown. We tested four major extracts of <i>M. charantia</i> and found that momordicine I reduced glioma cell viability without serious cytotoxic effects on astrocytes. Momordicine I suppressed glioma cell colony formation, proliferation, migration, and invasion. Momordicine I also induced apoptosis, intracellular reactive oxygen species (ROS) production, and senescence in glioma cells. Moreover, momordicine I decreased the oxidative phosphorylation capacity of glioma cells and inhibited tumor sphere formation in temozolomide (TMZ)-resistant GBM cells. We further explored whether the antiglioma effect of momordicine I may be related to cell cycle modulation and DLGPA5 expression. Our results indicate that the cytotoxic effect of momordicine I on glioma cells suggests its potential therapeutic application to GBM treatment. See also Figure 1(Fig. 1)."],"journal":["EXCLI journal"],"pagination":["482-498"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10391611"],"repository":["biostudies-literature"],"pubmed_title":["Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation."],"pmcid":["PMC10391611"],"pubmed_authors":["Chou CH","Huang LC","Kao Y","Tsai CK"],"additional_accession":[]},"is_claimable":false,"name":"Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation.","description":"Glioblastoma (GBM) is the most common type of primary brain tumor. Patients with GBM have poor survival outcomes. Isolated components of <i>Momordica charantia</i> have anticancer effects. However, the bioactivity of <i>M. charantia</i> extracts against GBM remains unknown. We tested four major extracts of <i>M. charantia</i> and found that momordicine I reduced glioma cell viability without serious cytotoxic effects on astrocytes. Momordicine I suppressed glioma cell colony formation, proliferation, migration, and invasion. Momordicine I also induced apoptosis, intracellular reactive oxygen species (ROS) production, and senescence in glioma cells. Moreover, momordicine I decreased the oxidative phosphorylation capacity of glioma cells and inhibited tumor sphere formation in temozolomide (TMZ)-resistant GBM cells. We further explored whether the antiglioma effect of momordicine I may be related to cell cycle modulation and DLGPA5 expression. Our results indicate that the cytotoxic effect of momordicine I on glioma cells suggests its potential therapeutic application to GBM treatment. See also Figure 1(Fig. 1).","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2024-11-21T09:14:16.675Z","creation":"2024-11-21T09:14:16.675Z"},"accession":"S-EPMC10391611","cross_references":{"pubmed":["37534227"],"doi":["10.17179/excli2023-6129"]}}